Prostate%20cancer Signs and Symptoms

Signs and Symptoms

Introduction

Second most common cancer in men; one of the most common cancers in men >50 years of age

Signs and Symptoms

Weak urinary stream, incomplete bladder emptying
Polyuria, nocturia
Hematuria
Erectile dysfunction
Pelvic pain, back pain, chest pain
Lower extremity weakness or numbness
Loss of bladder or bowel control

Risk Factors

Age (increased risk in men >50 years old)
Positive family history: 1st- or 2nd-degree relatives diagnosed with metastatic prostate, ovarian, breast (female ≤45 years old), colorectal, endometrial (≤50 years old) or pancreatic cancer, and those with ≥2 1st- or 2nd-degree relatives diagnosed with prostate, breast, colorectal or endometrial cancer at any age
Ethnicity (African ancestry, Ashkenazi Jewish descent)
Chemical exposures (toxic combustion products)
Genetic mutations: Breast cancer susceptibility gene 1 (BRCA1), breast cancer susceptibility gene 2 (BRCA2), ataxia telangiectasia mutated (ATM), checkpoint kinase 2 (CHEK2), homeobox B13 (HOXB13), epithelial cellular adhesion molecule (EPCAM), nibrin (NBN), tumor protein 53 (TP53), partner and localizer of BRCA2 (PALB2), deoxyribonucleicacid (DNA) mismatch repair genes [mutS homolog 2 (MSH2), mutL homolog 1 (MLH1), Lynch syndrome, mutS homolog 6 (MSH6), post-meiotic segregation increased 2 (PMS2)], insulin-like growth factor-1 (IGF-1)
Other risk factors under research include a positive medical history of inflammation of the prostate gland [eg prostatitis, sexually transmitted diseases (STDs), proliferative inflammatory atrophy (PIA)] and vasectomy

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib

Dr. Wong Seng Weng, Dr. Lee Guek Eng, 19 Mar 2021

In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.

ALL treatment: Current settings, future goals

Roshini Claire Anthony, 08 Jan 2021

Significant advancements in the treatment of acute lymphocytic leukaemia (ALL) in children have improved their outcomes. However, ALL treatment and eradication remain a major challenge in adults. In a recent webinar, two specialists from the US discussed current ALL treatment strategies and goals of future regimens.

Highlights from ESMO Asia 2017: Moving to a dual blockade strategy early in hormone receptor-positive breast cancer

22 Jan 2018

In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.